Skip to content
value.today
Optomed Oyj logo

Optomed Oyj

OPTOMED.HE
$73 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$19 M
For year ending December-2025
Net income
$-7 M
-38.9% margin
Official annual report (ESEF)
Employees
—

Optomed Oyj in brief

Optomed Oyj is a listed company in the Healthcare sector, based in Finland. Its last known market value was $73 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $19 M and a net loss of $7 M. Its shares trade under the symbol OPTOMED.HE (Nasdaq Nordic).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Optomed Oyj timeline

2 events, 2004–2019
  1. 2004
  2. 🏁
    · approximate
    Incorporated as Optomed Oyj
  3. 2019
  4. •
    Legal Entity Identifier issued
    LEI 7437009IVYWGEE4S7B77 registered.

Events of Optomed Oyj from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$43 M$86 M$130 M$173 M20232024

World rank over time

▼ down 2,832 places since 2022
2022-01-07: #20169#20,16920222022-12-25: #23937#23,93720222023-07-30: #24550#24,55020232024-01-05: #23001#23,0012024

Rank in Finland: #100 (Jan 2022) · #112 (Dec 2022) · #113 (Jul 2023) · #106 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-38.9%
Operating margin
-35.3%
Return on equity
-26.5%
Liabilities / assets
24.9%
Revenue growth
+18.4%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2024: revenue $16M, net income $-6M$16MFY24Fiscal year ending Dec 2025: revenue $19M, net income $-7M$19MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$19M+18.4%$-7M$-7M-38.9%
Dec 2024$16M—$-6M$-6M-36.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-3M$1M$-3M——
Dec 2024$-2M$0M$-2M——

Annual results

Revenue
$19 M
Operating income
$-7 M
Net income
$-7 M

For year ending December-2025 · source: official annual report (ESEF)

Balance sheet

Total assets
$38 M
Total liabilities
$9 M
Total equity
$28 M

As of December-2025

Mutual funds holding Optomed Oyj#

1 funds hold shares worth $1 M. Since their previous reports 1 added shares and 3 sold, buying $1 M net.
Mutual funds holding Optomed Oyj
FundSharesValueOf the companyOf the fundChange in sharesReport
🇸🇪 Handelsbanken Norden Index CriteriaHandelsbanken Fonder AB381,418$1 M—0.02%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Optomed Oyj scorecard#

Passes 1 of the 4 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 1
    • ✓Revenue grew in the newest year18.4%Revenue up 18.4% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-35.3%-35.3% against Healthcare's median of -7.7% (674 companies).
    • ✗Return on equity above 15%-28.4%-28.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Optomed Oyj's statements, beside the median of Healthcare.

Optomed Oyj: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-35.3%-7.7%
Net margin-38.9%-8.1%
Return on equity-28.4%-36.9%
Revenue growth18.4%10.2%
Free cash flow margin-17.8%-1.3%

2of 5on the Piotroski tests of financial strength

  • Net loss of $7 million.
  • Free cash flow was negative: -$3 million.

Optomed Oyj: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Optomed Oyj: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue17,09615,04015,10014,66014,85013,01114,977
Operating income−6,042−5,957−3,974−5,097−4,780−2,906−2,596
Interest and finance income5801,2174795697154528.0
Interest expense and finance costs1,2567761,0241,024263794365
Income before tax−6,718−5,516−4,519−5,551−4,327−3,247−2,952
Income tax−77−66−79−79−78−70−77
Net income including minority interests−6,640−5,450−4,441−5,472−4,249−3,177−2,875
Net income attributable to shareholders−6,640−5,450−4,441−5,472−4,249−3,177−2,875
Earnings per share, basic-0.34-0.29-0.27-0.37-0.32-0.24-0.32
Balance sheet
Cash and cash equivalents9,90910,4677,1188,5246,80410,60818,866
Receivables2,7562,4112,5833,5563,6582,6392,897
Inventory2,3821,9612,8202,9982,9362,5392,468
Current assets15,76515,69513,12816,09014,37116,78425,459
Property, plant and equipment894652710852433359406
Right-of-use (leased) assets1,2121,4561,4721,4481,2051,1651,075
Goodwill4,2564,2564,2564,2564,2564,2564,256
Non-current assets16,20816,08515,95115,21014,62614,28914,151
Total assets31,97331,78129,07931,30028,99831,07339,611
Current liabilities6,5935,5835,0525,2274,9123,4897,557
Long-term debt07901,6513,3803,8133,5205,104
Lease liabilities (non-current)8351,0179911,058818782699
Non-current liabilities1,3632,5613,6655,7317,0347,5129,416
Total liabilities7,9568,1448,71810,95711,94611,00116,973
Total equity24,01623,63720,36120,34217,05220,07322,637
Total liabilities and equity31,97331,78129,07931,30028,99831,07339,611
Cash-flow statement
Depreciation and amortization——————2,261
Cash from operating activities−2,482−1,596−615−2,370−2,940−2,801161
Capital expenditure−561−275−213−780−462−268−260
Intangible assets bought−1,796−1,843−2,199−2,249−2,112−1,553−1,175
Cash from investing activities−2,357−2,118−2,412−3,029−2,574−1,820−1,434
Debt issued————1,366−167176
Debt repaid−863−1,053−1,921−912−327−3,233−460
Shares issued5,9849,1824,3109,0121,0129223,000
Cash from financing activities4,1867,0811,6097,0031,637−3,69818,123
Exchange-rate effect on cash95−1913115736117
ReportESEFESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Optomed Oyj compares in Healthcare

  • Revenue$19 M · higher than 26% of 1,795
  • Net margin-38.9% · higher than 25% of 1,485
  • Revenue growth18.4% · higher than 67% of 1,003
CompanyMarket capP/ENet marginRev. growth
Optomed Oyj🇫🇮$73 M—-38.9%+18.4%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 15, 2026

Figures from Official annual report (ESEF), value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Optomed Oyj? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Optomed Oyj's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Optomed Oyj? Suggest a correction